{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:10:44Z","timestamp":1790683844874,"version":"4.1.0"},"reference-count":10,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,8,5]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>We report a case of complete tumour regression in a man in his 80s with in-transit melanoma following discontinuation of talimogene laherparepvec (T-VEC). The patient underwent a standard course of 1.0 mL of 1\u00d710\u2078 pfu\/mL T-VEC every 2 weeks. After 10 T-VEC injections over approximately 5 months, the lesion still displayed fluorine-18 fluorodeoxyglucose activity on positron emission tomography\/CT and biopsy-confirmed viable tumour. Due to side effects, including fatigue, headache and concern for a localised herpes simplex virus rash, the decision was made to discontinue T-VEC and perform surgical resection of the lesion. However, surgery was delayed by 8 weeks due to a minor stroke. After excision, the final pathology showed no residual melanoma, indicating a delayed, complete pathological response to T-VEC. This case may reflect the potential for continued or delayed anti-tumour immune activity after cessation of T-VEC and support further investigation into T-VEC\u2019s immune effects and timing of treatment in neoadjuvant settings.<\/jats:p>","DOI":"10.1136\/bcr-2025-269006","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:00:35Z","timestamp":1787148035000},"page":"e269006","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Complete tumour regression of in-transit melanoma following discontinuation of talimogene laherparepvec"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3535-6786","authenticated-orcid":false,"given":"Allan Samuel","family":"Chen","sequence":"first","affiliation":[{"name":"Surgery, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Proia","sequence":"additional","affiliation":[{"name":"Pathology, Duke University Medical Center, Durham, North Carolina, USA"},{"name":"Pathology, Campbell University Jerry M Wallace School of Osteopathic Medicine, Lillington, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ho","sequence":"additional","affiliation":[{"name":"Radiology, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mosca","sequence":"additional","affiliation":[{"name":"Surgery, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026081907001955000_19.8.e269006.1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10585-021-10100-3","article-title":"In-transit metastatic cutaneous melanoma: current management and future directions","volume":"39","author":"Patel","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"2026081907001955000_19.8.e269006.2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026081907001955000_19.8.e269006.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2667"},{"key":"2026081907001955000_19.8.e269006.4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026081907001955000_19.8.e269006.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343"},{"key":"2026081907001955000_19.8.e269006.6","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026081907001955000_19.8.e269006.7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","article-title":"Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience","volume":"228","author":"Louie","year":"2019","journal-title":"J Am Coll Surg"},{"key":"2026081907001955000_19.8.e269006.8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jdcr.2017.02.011","article-title":"Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec","volume":"3","author":"Blackmon","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2026081907001955000_19.8.e269006.9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0809-6"},{"key":"2026081907001955000_19.8.e269006.10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-269006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:00:37Z","timestamp":1787148037000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-269006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bcr-2025-269006"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-269006","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}